MEG 100
Alternative Names: MEG-100Latest Information Update: 28 Dec 2023
Price :
$50 *
At a glance
- Originator Tacitus Therapeutics
- Developer Mount Sinai Health System; Tacitus Therapeutics
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Thrombocytopenia
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Thrombocytopenia in USA (Parenteral, Infusion)
- 05 Oct 2020 MEG 100 is available for licensing as of 05 Oct 2020. https://tacitustherapeutics.com/about-us/collaborations/
- 05 Nov 2019 Preclinical trials in Thrombocytopenia in USA (Parenteral)